Evidence map›Paper›PMID 24445498›Full record

ReviewCurrent oncology reports2014

Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?

Daniel M Halperin, Gauri R Varadhachary

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Increased morbidity and mortality of a concomitant colectomy during a pancreaticoduodenectomy: an NSQIP propensity-score matched analysis.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2015
    Article
  13. Clinical Management of Pancreatic Cancer.Journal of the advanced practitioner in oncology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Daniel M HalperinDepartment of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Gauri R Varadhachary

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic adenocarcinoma represents a significant cause of morbidity and mortality in the modern era. Despite advances in the management of unresectable and advanced disease, the only potential avenue for cure at this time is resection. As our radiographic and surgical techniques have improved, we are better able to select patients who are the best candidates for a margin-negative resection, with or without the use of preoperative therapy. There is an emerging consensus on the definition of borderline resectable pancreatic cancer, but much work still needs to be done given the heterogeneous patient population, intervention, and outcome metrics used in previous retrospective and prospective studies. When designing future prospective trials of novel preoperative approaches, standardization of the stage of disease for the study population is essential to allow for accurate interpretation of study results. Ultimately, to make significant progress in localized pancreatic cancer, we urgently need effective novel therapeutic agents used in an optimal sequence with surgery.

Indexed as

AdenocarcinomaAntineoplastic AgentsChemoradiotherapy, AdjuvantClinical Trials as TopicHumansNeoplasm StagingPancreatic NeoplasmsPrognosisAntineoplastic Agents

Identifiers

PMID24445498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.